Home Pulmonary and cutaneous mucormycosis in two children with diabetes mellitus type 1
Article
Licensed
Unlicensed Requires Authentication

Pulmonary and cutaneous mucormycosis in two children with diabetes mellitus type 1

  • Nosrat Ghaemi , Sepide Bagheri and Sara Shirdelzade ORCID logo
Published/Copyright: April 6, 2021

Abstract

Objectives

Mucormycosis is a life-threatening condition that can be present in diabetes mellitus. Although the rhino-orbito-cerebral form is the most common, other types may be developed as well.

Case presentation

The present study reports two children with diabetes who had the cutaneous and pulmonary forms of mucormycosis. The first case was a four-year-old boy without a history of diabetes admitted due to loss of consciousness and a necrotic lesion on his hand. The second was an 11-year-old boy with dyspnea, polyuria, and polydipsia who had developed diabetes two years before, and whose chest X-ray had shown a pulmonary lesion. Both cases were treated with surgical implementation and appropriate antifungal therapy.

Conclusions

Mucormycosis is a fatal condition that can even be present at the onset of diabetes mellitus. Therefore, any diabetic patient with any presentation of respiratory symptoms such as coughs, or any cutaneous lesion should be examined carefully for mucormycosis after which prompt treatment must begin.


Corresponding author: Sara Shirdelzade, Instructor, MS of Pediatric Nursing, PhD Student of Nursing, Nursing Department, Neyshabur University of Medical Sciences, Neyshabur, Iran; and Nursing and Midwifery School, Mashhad University of Medical Sciences, Mashhad, Iran, E-mail:

  1. Conflict of interest: The authors declare that they have no conflict of interest.

  2. Ethical statement: The research related to human use has been complied with all the relevant national regulations, institutional policies and in accordance with the tenets of the Helsinki Declaration, and has been approved by the authors’ institutional review board or equivalent committee.

References

1. Jevalikar, G, Sudhanshu, S, Mahendru, S, Sarma, S, Farooqui, KJ, Mithal, A, et al.. Cutaneous mucormycosis as a presenting feature of type 1 diabetes in a boy–case report and review of the literature. J Pediatr Endocrinol Metabol 2018;31:689–92. https://doi.org/10.1515/jpem-2017-0404.Search in Google Scholar PubMed

2. Kasper, D, Fauci, A, Hauser, S, Longo, D, Jameson, J, Loscalzo, J. Harrison’s principles of internal medicine. New York: Mcgraw-hill; 2015, 19e.Search in Google Scholar

3. Bennett, JE, Dolin, R, Blaser, MJ. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases: 2-volume set. Philadelphia: Elsevier Health Sciences; 2014.Search in Google Scholar

4. Claustre, J, Larcher, R, Jouve, T, Truche, A-S, Nseir, S, Cadiet, J, et al.. Mucormycosis in intensive care unit: surgery is a major prognostic factor in patients with hematological malignancy. Ann Intensive Care 2020;10:1–12. https://doi.org/10.1186/s13613-020-00673-9.Search in Google Scholar PubMed PubMed Central

5. Thomas, L, Tay, SY, Howard, D, Falhammar, HJC. Mucormycosis in a 40-year-old woman with diabetic ketoacidosis. Can Med Assoc J 2020;192:E431–3. https://doi.org/10.1503/cmaj.191364.Search in Google Scholar PubMed PubMed Central

6. De Pauw, B, Walsh, TJ, Donnelly, JP, Stevens, DA, Edwards, JE, Calandra, T, et al.. Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group. Clin Infect Dis 2008;46:1813–21. https://doi.org/10.1086/588660.Search in Google Scholar PubMed PubMed Central

7. Roden, MM, Zaoutis, TE, Buchanan, WL, Knudsen, TA, Sarkisova, TA, Schaufele, RL, et al.. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005;41:634–53. https://doi.org/10.1086/432579.Search in Google Scholar PubMed

8. Guo, S, Liu, H, Tang, X, Yang, HJPI. Clinical characteristics and prognoses of pulmonary mucormycosis in four children. Pediatr Invest 2019;3:223–7. https://doi.org/10.1002/ped4.12161.Search in Google Scholar PubMed PubMed Central

9. Francis JR, VP, Bryant, P, Blyth, C. Mucormycosis in children: review and recommendations for management. J Pediatric Infect Dis Soc 2018;7:159–64. https://doi.org/10.1093/jpids/pix107.Search in Google Scholar PubMed

10. Pana, ZD, Seidel, D, Skiada, A, Groll, AH, Petrikkos, G, Cornely, OA, et al.. Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries. BMC Infect Dis 2016;16:667. https://doi.org/10.1186/s12879-016-2005-1.Search in Google Scholar PubMed PubMed Central

11. Elzein, F, Albarrag, A, Kalam, K, Arafah, M, Al-Baadani, A, Eltayeb, N, et al.. Mucormycosis: an 8-year experience of a tertiary care centre in Saudi Arabia. J Infect Public Health 2020;13:1774–9.10.1016/j.jiph.2020.08.002Search in Google Scholar PubMed

Received: 2020-10-23
Accepted: 2021-01-15
Published Online: 2021-04-06
Published in Print: 2021-07-27

© 2021 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Review Article
  3. Delivery factors and neonatal thyroid hormone levels: a systematic review
  4. Original Articles
  5. Birth prevalence of tetrahydrobiopterin deficiency in China: data from the national newborn screening program, 2013–2019
  6. Analysis of the CAG tract length in the Androgen Receptor gene in Mexican patients with nonsyndromic cryptorchidism
  7. Pituitary hypoplasia is the best MRI predictor of the severity and type of growth hormone deficiency in children with congenital growth hormone deficiency
  8. Urinary gonadotropin measurements by enhanced luminometric assays (LIA) for the evaluation of pubertal development
  9. Challenges in management of transient hyperinsulinism – a retrospective analysis of 36 severely affected children
  10. Who should return for an oral glucose tolerance test? A proposed clinical pathway based on retrospective analysis of 332 children
  11. Investigation of the prevalence of cardiovascular risk factors in obese patients diagnosed with metabolic syndrome in childhood and examination of left ventricular function by echocardiography
  12. Effect of l-carnitine supplementation on children and adolescents with nonalcoholic fatty liver disease (NAFLD): a randomized, triple-blind, placebo-controlled clinical trial
  13. Management of patients with X-linked hypophosphatemic rickets during Covid-19 pandemic lockdown
  14. Evaluation of the pathophysiological role of Fetuin A levels in adolescents with polycystic ovary syndrome
  15. Gonadotropins for testicular descent in cryptorchid congenital hypogonadotropic hypogonadism males beyond infancy
  16. Clinical characteristics and outcome of hospitalized children and adolescent patients with type 1 diabetes during the COVID-19 pandemic: data from a single center surveillance study in Egypt
  17. Letter to the Editor
  18. Revisiting the effect of GnRH analogue treatment on bone mineral density in young adolescents with gender dysphoria
  19. Case Reports
  20. Pulmonary and cutaneous mucormycosis in two children with diabetes mellitus type 1
  21. Pyruvate carboxylase deficiency type C as a differential diagnosis of diabetic ketoacidosis
  22. Barth syndrome with severe dilated cardiomyopathy and growth hormone resistance: a case report
  23. The utility of reverse phenotyping: a case of lysinuric protein intolerance presented with childhood osteoporosis
Downloaded on 1.11.2025 from https://www.degruyterbrill.com/document/doi/10.1515/jpem-2020-0623/html
Scroll to top button